NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TAGCyx Biotechnologies Inc.

TAGCyx Biotechnologies Inc.

Private
TokyoHealthcare & Life Scienceshttps://tagcyx.com/

Last Round

Grant

Apr 16, 2026

Total Funding Raised

$13.31M

Company Overview

TAGCyx Biotechnologies Inc. is a biotechnology company that develops oligonucleotide aptamer-based pharmaceuticals and medical devices using its proprietary Xenoligo® drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

aptamer therapeuticsoligonucleotide drugsdrug discovery platformnucleic acid drugsaptamer-based medical devicesbiotech R&Dapheresispreclinical biotechSELEXnucleic acid chemistrybiotech licensingnext-gen therapeuticssynthetic biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TAGCyx Biotechnologies Inc. Comparables

Compare TAGCyx Biotechnologies Inc. with similar companies based on industry and business-model similarity.

TAGCyx Biotechnologies Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Guardian Therapeutics
81%
Aptagen, LLC
79%
NeoVentures Biotechnology Inc.
78%

TAGCyx Biotechnologies Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 16, 2026
Series C ExtensionJul 7, 2021
Series CMay 18, 2020
Series BApr 27, 2018
Series AAug 31, 2016

TAGCyx Biotechnologies Inc. Investors

Notable investors and investment history

TAGCyx Biotechnologies Inc. investors
InvestorRounds
Japan Agency for Medical Research and DevelopmentGrant
Mizuho CapitalSeries B
UTEC (The University of Tokyo Edge Capital Partners)Series B, Series A
Nissay CapitalSeries A
株式会社ヘルスケア・イノベーションSeries C Extension
SBI HoldingsSeries C Extension
SMBC Venture CapitalSeries B, Series A

TAGCyx Biotechnologies Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TAGCyx Biotechnologies Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TAGCyx Biotechnologies Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTokyo
Employee Range2
Year Founded2007
Last FundingApr 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.